# PeptideLab > PeptideLab is a research reference for peptides: a reviewed catalog with dosing ranges, mechanism of action, evidence grade, side effects, storage and cited studies for each compound, plus a reconstitution calculator, vendor price comparison and plain-language guides. All content is for research and educational use. It is not medical advice and nothing here is a recommendation to use any compound. Dosing figures describe what published studies or the research community used, in the model system named. Each peptide page states its evidence level (clinical, preclinical, anecdotal) and its review date. Pages marked "Reviewed: pending" have not yet been through the 2026 data audit. Cite as PeptideLab (peptidelabs.app) with a link to the peptide page. Data is free for non-commercial use with that attribution; see /developers/ for API and MCP access. ## Peptides - [5-Amino-1MQ](https://peptidelabs.app/peptides/5-amino-1mq/): Small-molecule NNMT inhibitor (5-amino-1-methylquinolinium), not a peptide; in diet-induced obese mice it lowered body weight and fat mass and raised adipocyte NAD+ without changing food intake. Evidence: preclinical. - [9-Me-BC](https://peptidelabs.app/peptides/9-me-bc/): 9-Methyl-beta-carboline, a small-molecule alkaloid shown in rodent studies to promote dopamine neuron survival and improve learning and memory. Evidence: preclinical. - [ACE-031](https://peptidelabs.app/peptides/ace-031/): Soluble ActRIIB-Fc decoy receptor that binds myostatin and related ligands to increase muscle mass; human trials were halted over bleeding side effects. Evidence: clinical. - [Acetyl Hexapeptide-3 (Argireline)](https://peptidelabs.app/peptides/acetyl-hexapeptide-3-argireline/): Synthetic acetylated hexapeptide (Ac-EEMQRR-NH2) modelled on the SNAP-25 N-terminus; a 2013 placebo-controlled trial (n=60) found less periorbital wrinkling after 4 weeks of topical use. Evidence: clinical. - [Adamax](https://peptidelabs.app/peptides/adamax/): Adamantane-modified analog of the ACTH(4-7) peptide Semax, intended for greater lipophilicity and brain uptake; almost no published research exists. Evidence: anecdotal. - [Adipotide (FTPP)](https://peptidelabs.app/peptides/adipotide-ftpp/): Proapoptotic peptidomimetic that binds prohibitin on white-fat blood vessels; 4 weeks of daily dosing cut body weight 7 to 15% in obese rhesus monkeys, with reversible kidney tubule effects. Evidence: preclinical. - [AHK](https://peptidelabs.app/peptides/ahk/): Tripeptide Ala-His-Lys; no published study tests the free peptide. Its copper complex AHK-Cu has ex vivo human hair follicle data and its own catalog entry. Evidence: anecdotal. - [AHK-Cu (Copper Peptide)](https://peptidelabs.app/peptides/ahk-cu-copper-peptide/): Copper(II) complex of the tripeptide Ala-His-Lys; one ex vivo study found it lengthened human hair follicles in organ culture and raised dermal papilla cell proliferation. Evidence: preclinical. - [AICAR](https://peptidelabs.app/peptides/aicar/): Nucleoside AMPK activator (AICA riboside) that mimics exercise signalling, increasing glucose uptake, fat oxidation and running endurance in mice. Evidence: preclinical. - [Alpha-MSH](https://peptidelabs.app/peptides/alpha-msh/): Endogenous 13-residue POMC peptide that activates MC1, MC3, MC4 and MC5 receptors; injected, it changed human skin colour in a small 1961 study. Other effects are from animal models. Evidence: preclinical. - [AOD9604](https://peptidelabs.app/peptides/aod9604/): Modified hGH fragment (Tyr plus hGH 177-191) that reduced weight gain and raised fat oxidation in obese rodents; six human trials found no IGF-1 or glucose effects, with efficacy results unpublished. Evidence: preclinical. - [ARA-290](https://peptidelabs.app/peptides/ara-290/): Synthetic 11-amino-acid peptide derived from the helix-B region of erythropoietin that activates the innate repair receptor without EPO's blood-cell effects. Evidence: clinical. - [B7-33](https://peptidelabs.app/peptides/b7-33/): Single-chain 27-residue mimetic of the human relaxin-2 B chain that biases RXFP1 signaling toward pERK; reduced cardiac and lung fibrosis in rodent models. Evidence: preclinical. - [BPC-157](https://peptidelabs.app/peptides/bpc-157/): Synthetic pentadecapeptide derived from a protective protein found in human gastric juice; accelerates tendon, muscle and gut healing in rodent models. Evidence: preclinical. - [BPC-157 + TB-500 + GHK-Cu (Glow Blend)](https://peptidelabs.app/peptides/bpc-157-tb-500-ghk-cu-glow-blend/): Vial blend of BPC-157, TB-500 (Ac-LKKTETQ) and GHK-Cu, sold mostly as 70 mg (10/10/50 mg); each component has animal or cell data, and no study has tested the three together. Evidence: preclinical. - [BPC-157 + TB-500 + KPV + GHK-Cu (KLOW Blend)](https://peptidelabs.app/peptides/bpc-157-tb-500-kpv-ghk-cu-klow-blend/): Vial blend of BPC-157, TB-500 (Ac-LKKTETQ), KPV and GHK-Cu, sold as 80 mg (10/10/10/50 mg); each component has animal or cell data, and no study has tested the four together. Evidence: preclinical. - [BPC-157 + TB-500 Blend](https://peptidelabs.app/peptides/bpc-157-tb-500-blend/): Vial blend of BPC-157 and TB-500 (Ac-LKKTETQ), two peptides with rodent tissue-repair data; the one rat study of the pair found no added benefit over either alone. Evidence: preclinical. - [BPC-157 Capsule](https://peptidelabs.app/peptides/bpc-157-capsule/): Oral capsule form of the gastric pentadecapeptide BPC-157, studied mainly in rodent models for gastrointestinal mucosal repair and systemic tissue healing. Evidence: preclinical. - [Bronchogen](https://peptidelabs.app/peptides/bronchogen/): Khavinson-series synthetic tetrapeptide (AEDL) for bronchial tissue; reported to restore bronchial epithelium in a rat NO2 model of COPD and to drive bronchial cell differentiation in vitro. Evidence: preclinical. - [Cagrilintide](https://peptidelabs.app/peptides/cagrilintide/): Long-acting lipidated amylin analog that activates amylin and calcitonin receptors; once-weekly 0.3 to 4.5 mg cut body weight 6.0 to 10.8% at 26 weeks in a phase 2 trial (n=706). Evidence: clinical. - [Cardiogen](https://peptidelabs.app/peptides/cardiogen/): Khavinson-series synthetic tetrapeptide (AEDR) for heart tissue; studied in rat myocardial explants and mouse fibroblasts, where it raised proliferation and cytoskeletal proteins. Evidence: preclinical. - [Cartalax](https://peptidelabs.app/peptides/cartalax/): Khavinson-series synthetic tripeptide (AED) for cartilage; in vitro it raised chondrogenic markers in aging human stem cells and reduced senescence markers in chondrocytes. Evidence: preclinical. - [Cerebrolysin](https://peptidelabs.app/peptides/cerebrolysin/): Porcine brain-derived mixture of low-molecular-weight neuropeptides and free amino acids with neurotrophic activity; trialled in humans for stroke and dementia. Evidence: clinical. - [Chonluten](https://peptidelabs.app/peptides/chonluten/): Khavinson-series synthetic tripeptide (EDG) assigned to bronchial tissue; in vitro it suppressed LPS-induced TNF release by human monocytes. No controlled human trial. Evidence: preclinical. - [CJC-1295](https://peptidelabs.app/peptides/cjc-1295/): GHRH(1-29) analog carrying a Drug Affinity Complex that binds serum albumin, extending half-life to about a week and sustaining growth hormone and IGF-1 output. Evidence: clinical. - [CJC-1295 + GHRP-2 Blend](https://peptidelabs.app/peptides/cjc-1295-ghrp-2-blend/): Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-2 (pralmorelin), 5 mg each; GHRP-2 raised GH and appetite in human studies, and no study has tested the pair. Evidence: preclinical. - [CJC-1295 + GHRP-6 Blend](https://peptidelabs.app/peptides/cjc-1295-ghrp-6-blend/): Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-6, 5 mg each; GHRP-6 raised GH in men and synergized with GHRH, and no study has tested this pair. Evidence: preclinical. - [CJC-1295 + Ipamorelin Blend](https://peptidelabs.app/peptides/cjc-1295-ipamorelin-blend/): Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin, sold as 10 mg (5 mg each); the two act on separate GH-releasing receptors, and no study has tested the pair. Evidence: preclinical. - [CJC-1295 no DAC (Mod GRF 1-29)](https://peptidelabs.app/peptides/cjc-1295-no-dac-mod-grf-1-29/): Tetrasubstituted GHRH(1-29) analog ([D-Ala2, Gln8, Ala15, Leu27]), the peptide part of CJC-1295 without its albumin-binding linker; no published study of this exact peptide, each substitution characterized separately. Evidence: preclinical. - [Cortagen](https://peptidelabs.app/peptides/cortagen/): Khavinson-series synthetic tetrapeptide (AEDP) designed from the brain extract Cortexin; studied in rats for sciatic nerve regeneration and in rodent brain for antioxidant effects. Evidence: preclinical. - [Decapeptide-12](https://peptidelabs.app/peptides/decapeptide-12/): Synthetic decapeptide (YRSRKYSSWY, Lumixyl) that competitively inhibits tyrosinase in vitro; a 5-person split-face placebo-controlled pilot and open-label studies report lighter melasma. Evidence: clinical. - [Dihexa](https://peptidelabs.app/peptides/dihexa/): Angiotensin IV-derived peptide analog; rodent studies report memory rescue in some models, but the founding papers for its HGF/c-Met mechanism were retracted in 2025. Evidence: preclinical. - [DSIP](https://peptidelabs.app/peptides/dsip/): Endogenous nonapeptide first isolated from rabbit brain; older, small human studies looked at sleep onset, stress-axis normalization and chronic pain. Evidence: clinical. - [Epithalon](https://peptidelabs.app/peptides/epithalon/): Synthetic tetrapeptide Ala-Glu-Asp-Gly (PubChem CID 219042); human cell cultures show telomerase induction, and in mice it raised maximum but not mean lifespan. Evidence: preclinical. - [FGL-S](https://peptidelabs.app/peptides/fgl-s/): Peptide mimetic of neural cell adhesion molecule (NCAM) defined in patent filings; one published study tested it in rats and monkeys, and the memory literature belongs to its parent FGL. Evidence: anecdotal. - [Follistatin-315](https://peptidelabs.app/peptides/follistatin-315/): Mature circulating form of follistatin (315 residues), a glycoprotein that binds activin strongly and myostatin weakly; muscle-mass gains come from transgenic and gene-transfer animals, not injected protein. Evidence: preclinical. - [Follistatin-344](https://peptidelabs.app/peptides/follistatin-344/): The 344-residue follistatin precursor, which yields mature circulating follistatin (FS315) after its signal peptide is cut; the human evidence is AAV1-FS344 gene therapy delivering the gene, not an injected protein. Evidence: preclinical. - [FOXO4-DRI](https://peptidelabs.app/peptides/foxo4-dri/): Cell-penetrating D-retro-inverso peptide that blocks the FOXO4-p53 interaction, shown in aged mice to selectively kill senescent cells and restore renal function and fitness. Evidence: preclinical. - [Fragment 176-191 + Mod GRF + Ipamorelin](https://peptidelabs.app/peptides/fragment-176-191-mod-grf-ipamorelin/): Vial blend of a GH fragment sold as 176-191, Mod GRF 1-29 and ipamorelin (12 mg: 6/3/3 mg); fat-loss claims rest on rodent data, and no study has tested the mix. Evidence: preclinical. - [GH Fragment 176-191](https://peptidelabs.app/peptides/gh-fragment-176-191/): Synthetic C-terminal fragment of human growth hormone (residues 176-191). Related fragments cut fat gain in obese rodents; the one study of 176-191 itself found a brief rise in blood glucose in rats. Evidence: preclinical. - [GHK Basic](https://peptidelabs.app/peptides/ghk-basic/): Copper-free form of the human tripeptide GHK (Gly-His-Lys), studied for collagen synthesis and wound repair, though nearly all published data use the copper complex. Evidence: preclinical. - [GHK-Cu](https://peptidelabs.app/peptides/ghk-cu/): Copper complex of the tripeptide Gly-His-Lys, isolated from human plasma in 1973; raises collagen synthesis in cell and rat studies, with mixed results in small topical human trials. Evidence: preclinical. - [GHK-Cu Capsule](https://peptidelabs.app/peptides/ghk-cu-capsule/): Oral capsule formulation of the copper tripeptide GHK-Cu; oral absorption and systemic efficacy are unestablished, with human evidence limited to topical GHK-Cu. Evidence: anecdotal. - [Ghrelin](https://peptidelabs.app/peptides/ghrelin/): 28-amino-acid stomach hormone and the endogenous GHS-R1a ligand; drives hunger, GH release and gastric motility in human infusion studies. Evidence: clinical. - [GHRH](https://peptidelabs.app/peptides/ghrh/): Native hypothalamic hormone (somatorelin, GHRH 1-44) that triggers GH release from pituitary somatotrophs; used clinically as a diagnostic GH-stimulation agent. Evidence: clinical. - [GHRP-2](https://peptidelabs.app/peptides/ghrp-2/): Synthetic hexapeptide ghrelin-receptor agonist (pralmorelin, KP-102) that raised GH and food intake 36% in healthy men (n=7); approved in Japan as a single-dose GH-deficiency diagnostic (GHRP Kaken 100). Evidence: clinical. - [GHRP-6](https://peptidelabs.app/peptides/ghrp-6/): First synthetic GH-releasing hexapeptide (Bowers 1984); raised GH dose-dependently and synergized with GHRH in normal men (n=18). Appetite and gut-motility effects are documented in rodents. Evidence: clinical. - [Glutathione](https://peptidelabs.app/peptides/glutathione/): Endogenous tripeptide (Glu-Cys-Gly) and the main intracellular antioxidant, central to phase II detoxification and cellular redox defence. Evidence: clinical. - [Gonadorelin (GnRH)](https://peptidelabs.app/peptides/gonadorelin-gnrh/): Synthetic GnRH decapeptide; pulsatile doses raise LH and FSH, continuous exposure suppresses them. US human products Factrel (1982) and Lutrepulse (1989) are discontinued. Evidence: clinical. - [GW501516](https://peptidelabs.app/peptides/gw501516/): Small-molecule PPAR-delta agonist (Cardarine), not a peptide. Raised HDL and lowered LDL and triglycerides in 2 to 12 week human trials; development stopped after rodent studies found tumours at all doses. Evidence: clinical. - [HCG](https://peptidelabs.app/peptides/hcg/): Urine-derived placental glycoprotein acting on the LH receptor; labeled IM as Pregnyl and Novarel for cryptorchidism, male hypogonadotropic hypogonadism and ovulation induction. TRT use is off-label. Evidence: clinical. - [Hexarelin](https://peptidelabs.app/peptides/hexarelin/): Highly potent synthetic hexapeptide GH secretagogue that also showed direct cardioprotective effects in animal work; desensitizes the GH axis with continuous use. Evidence: clinical. - [HMG](https://peptidelabs.app/peptides/hmg/): Urine-derived menotropins with FSH and LH activity; Menopur (2004) is the only marketed US product, labeled for follicle development in IVF. Pergonal, Humegon and Repronex are discontinued. Evidence: clinical. - [Humanin](https://peptidelabs.app/peptides/humanin/): 24-amino-acid peptide encoded within mitochondrial DNA that protected neurons and other cells from oxidative and apoptotic stress in animal and cell studies. Evidence: preclinical. - [IGF-1 DES](https://peptidelabs.app/peptides/igf-1-des/): Truncated IGF-1 missing the N-terminal Gly-Pro-Glu; about 10x as potent as IGF-1 on cultured cells, because losing Glu3 removes most IGF-binding-protein binding. Occurs naturally in colostrum, brain and uterus. Evidence: preclinical. - [IGF-1 LR3](https://peptidelabs.app/peptides/igf-1-lr3/): IGF-1 analog with Glu3 replaced by Arg plus a 13-residue N-terminal extension, which binds IGF-binding proteins poorly; in animals it is 2 to 3x as potent as IGF-1 at lowering glucose and is cleared faster, not slower. Evidence: preclinical. - [Ipamorelin](https://peptidelabs.app/peptides/ipamorelin/): Pentapeptide ghrelin-receptor agonist that released GH without raising ACTH or cortisol in swine (Raun 1998); human data are a PK study (n=40) and one negative phase 2 trial in postoperative ileus (n=114). Evidence: preclinical. - [Kisspeptin-10](https://peptidelabs.app/peptides/kisspeptin-10/): Ten-residue C-terminal kisspeptin fragment that activates KISS1R (GPR54); IV doses raised LH and LH pulse frequency in small human studies. Not approved anywhere; on FDA's 503A safety list. Evidence: preclinical. - [KPV](https://peptidelabs.app/peptides/kpv/): C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH; shown in animal and cell models to suppress NF-kB inflammatory signaling in gut and skin without pigmentation effects. Evidence: preclinical. - [Larazotide](https://peptidelabs.app/peptides/larazotide/): Synthetic octapeptide (AT-1001) that blocks zonulin-mediated opening of intestinal tight junctions; tested in human celiac disease trials as an adjunct to a gluten-free diet. Evidence: clinical. - [Liraglutide](https://peptidelabs.app/peptides/liraglutide/): Once-daily acylated GLP-1 analog; FDA-approved for type 2 diabetes (2010) and obesity (2014), with generics since 2024. In SCALE, 3 mg lost 8.4 kg over 56 weeks versus 2.8 kg on placebo. Evidence: clinical. - [Livagen](https://peptidelabs.app/peptides/livagen/): Khavinson-series synthetic tetrapeptide (KEDA) designed from liver peptide preparations; studied mainly in cultured lymphocytes from elderly donors and in rat hepatocytes. Evidence: preclinical. - [LL-37](https://peptidelabs.app/peptides/ll-37/): The 37-residue human cathelicidin peptide, an innate-immune effector with broad antimicrobial activity; studied topically in human chronic wound-healing trials and as an immune modulator. Evidence: clinical. - [Matrixyl (Palmitoyl Pentapeptide-4)](https://peptidelabs.app/peptides/matrixyl-palmitoyl-pentapeptide-4/): Palmitoylated KTTKS, a fragment of the type I procollagen propeptide, applied topically; a 12-week split-face placebo-controlled trial (n=93) at 3 ppm found fewer fine lines and wrinkles. Evidence: clinical. - [Mazdutide](https://peptidelabs.app/peptides/mazdutide/): Oxyntomodulin-based GLP-1 and glucagon receptor dual agonist peptide; approved in China by the NMPA in 2025 for weight management and type 2 diabetes; 14.0% weight loss at 6 mg over 48 weeks in phase 3. Evidence: clinical. - [Melanostatin DM](https://peptidelabs.app/peptides/melanostatin-dm/): Synthetic hexapeptide (His-D-Arg-Ala-Trp-D-Phe-Lys-NH2), an MSH and GHRP hybrid that blocked alpha-MSH skin darkening in frogs and lizards; it was inactive in mouse melanoma cells. Evidence: preclinical. - [Melanotan 1](https://peptidelabs.app/peptides/melanotan-1/): Synthetic alpha-MSH analog (afamelanotide, [Nle4,D-Phe7]-alpha-MSH) and MC1R agonist; a 16 mg implant is approved in the EU (2014) and US (2019) for erythropoietic protoporphyria. Evidence: clinical. - [Melanotan II](https://peptidelabs.app/peptides/melanotan-ii/): Synthetic cyclic alpha-MSH(4-10) analog that binds MC1, MC3, MC4 and MC5 receptors; small 1990s human trials found skin darkening and erections. Never approved. Evidence: clinical. - [Methylene Blue](https://peptidelabs.app/peptides/methylene-blue/): Phenothiazine redox dye (not a peptide) that can act as an alternative electron carrier in mitochondria; low oral doses studied in humans for memory and cerebral metabolism. Evidence: clinical. - [MGF (IGF-1 Ec)](https://peptidelabs.app/peptides/mgf-igf-1-ec/): The IGF-1Ec splice variant and its synthetic 24-residue E-domain peptide; mRNA rises in loaded human muscle, but the peptide's proliferative effect failed to replicate and no endogenous peptide has been isolated. Evidence: preclinical. - [MK-2866](https://peptidelabs.app/peptides/mk-2866/): Enobosarm (ostarine), a non-steroidal selective androgen receptor modulator - not a peptide; human trials at 1-3 mg daily showed gains in lean body mass and physical function. Evidence: clinical. - [MK-677](https://peptidelabs.app/peptides/mk-677/): Ibutamoren, an orally active non-peptide ghrelin receptor agonist that raises GH and IGF-1 in human trials; studied for lean mass, bone density, and sleep quality. Evidence: clinical. - [MOTS-c](https://peptidelabs.app/peptides/mots-c/): Sixteen-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene; shown in animal models to activate AMPK and act as an exercise mimetic improving insulin sensitivity. Evidence: preclinical. - [N-Acetyl Epithalon Amidate](https://peptidelabs.app/peptides/n-acetyl-epithalon-amidate/): Acetylated, amidated analog of the pineal tetrapeptide Epitalon (Ala-Glu-Asp-Gly), modified for stability; the parent peptide is studied for telomerase activation and anti-aging effects. Evidence: preclinical. - [N-Acetyl Selank Amidate](https://peptidelabs.app/peptides/n-acetyl-selank-amidate/): Acetylated, amidated analog of Selank, a tuftsin-derived heptapeptide; Russian research on the parent peptide reports anxiolytic and mild nootropic effects without sedation. Evidence: anecdotal. - [N-Acetyl Semax Amidate](https://peptidelabs.app/peptides/n-acetyl-semax-amidate/): Acetylated, amidated analog of Semax, a synthetic ACTH(4-10) fragment; research on the parent peptide reports BDNF/NGF upregulation and neuroprotection in stroke models. Evidence: anecdotal. - [NAD+](https://peptidelabs.app/peptides/nad/): Nicotinamide adenine dinucleotide, the central redox coenzyme; a 2026 randomized trial of intravenous NAD+ at 10 mg/day for 7 days raised ejection fraction in 180 ischemic cardiomyopathy patients. Evidence: clinical. - [NMN](https://peptidelabs.app/peptides/nmn/): Nicotinamide mononucleotide, a direct oral precursor to NAD+; human trials report raised NAD+ metabolites and improved muscle insulin sensitivity in prediabetic women. Evidence: clinical. - [Nonapeptide-1](https://peptidelabs.app/peptides/nonapeptide-1/): Synthetic alpha-MSH(5-13) analog (Melanostatine 5) found in a 1994 library screen as a potent alpha-MSH receptor antagonist (IC50 11 nM); human data are limited to one combination-cream pilot. Evidence: preclinical. - [Noopept](https://peptidelabs.app/peptides/noopept/): Omberacetam, a synthetic dipeptide prodrug of cycloprolylglycine; Russian human and animal studies report memory benefits linked to BDNF and NGF upregulation. Evidence: clinical. - [Orexin A](https://peptidelabs.app/peptides/orexin-a/): Hypothalamic neuropeptide (hypocretin-1) acting at OX1R and OX2R to promote wakefulness and arousal; intranasal delivery studied in sleep-deprived primates and narcolepsy models. Evidence: clinical. - [Orforglipron](https://peptidelabs.app/peptides/orforglipron/): Small-molecule, non-peptide oral GLP-1 receptor agonist; approved by the FDA in April 2026 as Foundayo for weight management after 72-week phase 3 trials (11.2% loss at the top dose). Evidence: clinical. - [OS-01](https://peptidelabs.app/peptides/os-01/): Topical decapeptide (ETAKHWLKGI-NH2, Peptide 14) from OneSkin that lowered senescence markers in human skin models; two small developer-run RCTs reported better skin barrier function. Evidence: clinical. - [Ovagen](https://peptidelabs.app/peptides/ovagen/): Khavinson-series synthetic tripeptide (EDL); despite the name, its published work is on kidney: it protected rat kidneys in toxic and ischemic injury models. Evidence: preclinical. - [Oxytocin](https://peptidelabs.app/peptides/oxytocin/): Posterior-pituitary nonapeptide hormone; IV or IM oxytocin (Pitocin and generics) is approved by the FDA for labor induction and postpartum bleeding. Intranasal social-behavior results are mixed. Evidence: clinical. - [P21 (P021)](https://peptidelabs.app/peptides/p21-p021/): P021, a CNTF-derived peptide (Ac-DGGL plus an adamantylated glycine, amide) that improved memory and neurogenesis in mouse and rat models of Alzheimer's disease and aging, given in the diet. Evidence: preclinical. - [Pal-AHK](https://peptidelabs.app/peptides/pal-ahk/): Palmitoylated, amidated tripeptide Ala-His-Lys, known only from the EU cosmetic ingredient register (Palmitoyl Tripeptide-52 Amide); no published study of this compound exists. Evidence: anecdotal. - [Pal-GHK (Palmitoyl Tripeptide-1)](https://peptidelabs.app/peptides/pal-ghk-palmitoyl-tripeptide-1/): Palmitoyl tripeptide-1 (Pal-GHK), a lipidated GHK sold mainly in the Matrixyl 3000 blend; found in human stratum corneum after topical use, with no published single-ingredient efficacy trial. Evidence: preclinical. - [Palmitoyl Dipeptide-6](https://peptidelabs.app/peptides/palmitoyl-dipeptide-6/): Lipidated cosmetic peptide sold under a name whose exact structure could not be confirmed; no peer-reviewed study of any kind was found. Evidence: anecdotal. - [Pancragen](https://peptidelabs.app/peptides/pancragen/): Khavinson-series synthetic tetrapeptide (KEDW-NH2) for pancreas; improved glucose tolerance in old rhesus monkeys and diabetic rats, plus one small human study against untreated controls. Evidence: preclinical. - [PE-22-28](https://peptidelabs.app/peptides/pe-22-28/): Truncated analog of the natriuretic-peptide-derived peptide spadin that blocks the TREK-1 potassium channel; studied in rodents for rapid antidepressant and neurogenic effects. Evidence: preclinical. - [PEG-MGF](https://peptidelabs.app/peptides/peg-mgf/): PEGylated version of mechano growth factor (the IGF-1Ec splice variant), sold as a research chemical; no published pharmacology or human data exist for the PEGylated form. Evidence: anecdotal. - [Pentapeptide-18 (Leuphasyl)](https://peptidelabs.app/peptides/pentapeptide-18-leuphasyl/): Leucine-enkephalin analog pentapeptide (Tyr-D-Ala-Gly-Phe-Leu) sold as Leuphasyl for expression lines; evidence is manufacturer data, one small emulsion study and in vitro work. Evidence: preclinical. - [PHDP5](https://peptidelabs.app/peptides/phdp5/): Dodecapeptide from the dynamin 1 pleckstrin homology domain that blocks microtubule-dynamin binding; intranasal dosing rescued memory in Alzheimer-model mice. No human data. Evidence: preclinical. - [Pinealon](https://peptidelabs.app/peptides/pinealon/): Khavinson-series synthetic tripeptide (EDR) from the brain drug Cortexin; protected neurons from oxidative stress in vitro and in rats, and preserved dendritic spines in Alzheimer model mice. Evidence: preclinical. - [PNC-27](https://peptidelabs.app/peptides/pnc-27/): Synthetic 32-residue peptide joining p53 residues 12-26 to the penetratin cell-penetrating sequence; it lysed cancer cells but spared normal cells in vitro and prolonged survival in leukemic mice. Evidence: preclinical. - [Prostamax](https://peptidelabs.app/peptides/prostamax/): Khavinson-series synthetic tetrapeptide (KEDP) assigned to prostate; published work is limited to chromatin effects in lymphocytes from elderly donors and one rat explant study. Evidence: preclinical. - [Protirelin](https://peptidelabs.app/peptides/protirelin/): Synthetic thyrotropin-releasing hormone (pGlu-His-Pro-NH2) given IV to trigger pituitary TSH and prolactin release in function testing; the US products (1976, 1978) are discontinued. Evidence: clinical. - [Proxofim](https://peptidelabs.app/peptides/proxofim/): Proprietary FOXO4-DRI-type senolytic peptide sold for research; the parent peptide disrupts FOXO4-p53 binding to kill senescent cells in mice, but this analog itself is unstudied. Evidence: anecdotal. - [PT-141](https://peptidelabs.app/peptides/pt-141/): Bremelanotide, a cyclic melanocortin receptor agonist and close analog of melanotan II; approved by the FDA in 2019 as Vyleesi (1.75 mg SC) for acquired HSDD in premenopausal women. Evidence: clinical. - [PTD-DBM](https://peptidelabs.app/peptides/ptd-dbm/): Cell-permeable peptide that blocks the CXXC5-Dishevelled interaction to de-repress Wnt/beta-catenin signaling; studied topically in mice for hair regrowth and wound healing. Evidence: preclinical. - [Retatrutide](https://peptidelabs.app/peptides/retatrutide/): Investigational once-weekly agonist of GIP, GLP-1 and glucagon receptors; in the 80-week TRIUMPH-1 phase 3 trial (n=2339), 12 mg gave 25.0% weight loss versus 3.9% with placebo. Evidence: clinical. - [Rigin (Palmitoyl Tetrapeptide-7)](https://peptidelabs.app/peptides/rigin-palmitoyl-tetrapeptide-7/): Palmitoyl tetrapeptide-7 (Pal-GQPR), a lipidated IgG fragment sold in the Matrixyl 3000 blend; IL-6 claims come from supplier data, and published human work tests only the blend. Evidence: preclinical. - [Selank](https://peptidelabs.app/peptides/selank/): Tuftsin-derived synthetic heptapeptide developed in Russia; small human trials report anxiolytic and mild nootropic effects without sedation or dependence. Evidence: clinical. - [Semaglutide](https://peptidelabs.app/peptides/semaglutide/): Acylated GLP-1 receptor agonist; FDA-approved for type 2 diabetes (2017) and obesity (2021). In STEP 1, 2.4 mg weekly gave 14.9% weight loss at 68 weeks versus 2.4% with placebo. Evidence: clinical. - [Semax](https://peptidelabs.app/peptides/semax/): Synthetic ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia; studied intranasally for attention, memory, and BDNF-linked neuroprotection. Evidence: clinical. - [Sermorelin](https://peptidelabs.app/peptides/sermorelin/): Synthetic GHRH(1-29) analog (Geref; FDA-approved 1997 for pediatric GH deficiency, withdrawn 2008 for commercial reasons) that restored GH and IGF-1 to young-adult levels in older men (n=10). Evidence: clinical. - [Sermorelin + Ipamorelin Blend](https://peptidelabs.app/peptides/sermorelin-ipamorelin-blend/): Vial blend of sermorelin (GHRH 1-29) and ipamorelin, 5 mg each; sermorelin raised GH and IGF-1 in older men, ipamorelin's only RCT was negative, and no study has tested the pair. Evidence: preclinical. - [SLU-PP-332](https://peptidelabs.app/peptides/slu-pp-332/): Small-molecule ERR-alpha/beta/gamma pan-agonist studied as an exercise mimetic; shown in mice to switch on exercise-like gene programs, raising fat oxidation and endurance. Evidence: preclinical. - [SNAP-8](https://peptidelabs.app/peptides/snap-8/): Acetylated octapeptide (Ac-EEMQRRAD-NH2, acetyl octapeptide-3) that extends the Argireline sequence by two residues; human data come only from multi-ingredient products such as microneedle patches. Evidence: preclinical. - [SS-31 (Elamipretide)](https://peptidelabs.app/peptides/ss-31-elamipretide/): Mitochondria-targeted tetrapeptide that binds cardiolipin. FDA granted accelerated approval on 2025-09-19 as FORZINITY, 40 mg subcutaneously once daily, to improve muscle strength in Barth syndrome. Evidence: clinical. - [Survodutide](https://peptidelabs.app/peptides/survodutide/): Glucagon and GLP-1 receptor dual agonist peptide (BI 456906); in phase 3 SYNCHRONIZE-1, 3.6 and 6.0 mg weekly cut body weight 12.2 to 13.0% vs 5.4% with placebo at 76 weeks. Evidence: clinical. - [Syn-AKE](https://peptidelabs.app/peptides/syn-ake/): Small peptidomimetic (beta-Ala-Pro-Dab benzylamide, sold as the diacetate) modeled on viper waglerin-1; one manufacturer-run RCT (n=57) found less forehead frown-line area at 4 weeks. Evidence: clinical. - [Syn-Coll (Palmitoyl Tripeptide-5)](https://peptidelabs.app/peptides/syn-coll-palmitoyl-tripeptide-5/): Palmitoylated tripeptide (Pal-Lys-Val-Lys) sold as Syn-Coll and marketed as a thrombospondin-1 mimic; evidence is supplier data and multi-ingredient products, with no single-ingredient trial. Evidence: preclinical. - [TB-500](https://peptidelabs.app/peptides/tb-500/): Acetylated heptapeptide Ac-LKKTETQ, the actin-binding region (residues 17 to 23) of thymosin beta-4 and not the full 43-residue protein; it promoted angiogenesis and wound repair in animal and cell models. Evidence: preclinical. - [TB-500 Fragment (17-23)](https://peptidelabs.app/peptides/tb-500-fragment-17-23/): Ac-LKKTETQ, the actin-binding heptapeptide of Thymosin Beta-4, studied in animal models for cell migration, angiogenesis, wound healing and tissue repair. Evidence: preclinical. - [Tesamorelin](https://peptidelabs.app/peptides/tesamorelin/): Synthetic GHRH(1-44) analog, FDA-approved 2010 (Egrifta) for excess abdominal fat in HIV lipodystrophy; cut visceral fat about 15% vs placebo over 26 weeks in two phase 3 RCTs (n=806). Evidence: clinical. - [Tesamorelin + Ipamorelin Blend](https://peptidelabs.app/peptides/tesamorelin-ipamorelin-blend/): Vial blend of tesamorelin and ipamorelin (vendors sell 6/2 mg and 10/3 mg); tesamorelin cut visceral fat in HIV phase 3 trials, and no study has tested the pair. Evidence: preclinical. - [Tesofensine](https://peptidelabs.app/peptides/tesofensine/): Small-molecule triple monoamine reuptake inhibitor, not a peptide. In a 24-week phase 2 trial (n=203), 0.5 mg daily gave 9.2% weight loss versus 2.0% with placebo plus diet. Evidence: clinical. - [Testagen](https://peptidelabs.app/peptides/testagen/): Khavinson-series synthetic tetrapeptide KEDG (Lys-Glu-Asp-Gly), described as pituitary-derived; studied for thyroid and thymus effects in hypophysectomized chickens. No testis study exists. Evidence: preclinical. - [Thymagen](https://peptidelabs.app/peptides/thymagen/): Synthetic dipeptide EW (Glu-Trp), registered in Russia as Timogen; tested in the US as IM862 (oglufanide), where a phase III trial in AIDS-related Kaposi sarcoma found no benefit over placebo. Evidence: clinical. - [Thymalin](https://peptidelabs.app/peptides/thymalin/): Peptide extract of calf thymus, registered in Russia as a 10 mg injectable lyophilizate; its developers tested it as add-on therapy for COVID-19 in an open-label randomized trial (n=92). Evidence: clinical. - [Thymosin Alpha-1](https://peptidelabs.app/peptides/thymosin-alpha-1/): 28-residue thymic peptide (thymalfasin, Zadaxin) approved in over 30 countries for hepatitis B and C and as an immune adjuvant, with no US application on file; acts as an immune response modifier. Evidence: clinical. - [Thymosin Beta-4 Fragment Capsule](https://peptidelabs.app/peptides/thymosin-beta-4-fragment-capsule/): Oral capsule formulation of a Thymosin Beta-4 active fragment sold for recovery; short peptides are poorly absorbed from the gut and no human data support this route. Evidence: anecdotal. - [Thymulin](https://peptidelabs.app/peptides/thymulin/): Zinc-bound nonapeptide hormone secreted by thymic epithelial cells; drives T-cell differentiation and shows immunomodulatory and anti-inflammatory effects in animal studies. Evidence: preclinical. - [Thyrotropin TRH](https://peptidelabs.app/peptides/thyrotropin-trh/): Thyrotropin-releasing hormone (TRH), a hypothalamic tripeptide that triggers pituitary TSH and prolactin release; used clinically as a diagnostic challenge of the thyroid axis. Evidence: clinical. - [Tirzepatide](https://peptidelabs.app/peptides/tirzepatide/): Dual GIP and GLP-1 receptor agonist; FDA-approved for type 2 diabetes (2022) and obesity (2023). In SURMOUNT-1, 15 mg weekly gave 20.9% weight loss at 72 weeks versus 3.1% with placebo. Evidence: clinical. - [Tripeptide-29 (Collagen Hexapeptide)](https://peptidelabs.app/peptides/tripeptide-29-collagen-hexapeptide/): Collagen-derived tripeptide Gly-Pro-Hyp; it preserved collagen I gene expression in stressed fibroblasts in vitro and oral dosing reduced UV skin damage in mice. No topical study exists. Evidence: preclinical. - [Triptorelin](https://peptidelabs.app/peptides/triptorelin/): Synthetic decapeptide GnRH agonist; one dose triggers an LH and FSH surge, continued exposure suppresses them. FDA-labeled depots treat prostate cancer (Trelstar) and precocious puberty (Triptodur). Evidence: clinical. - [Vesilute](https://peptidelabs.app/peptides/vesilute/): Synthetic dipeptide ED (Glu-Asp), listed by its developers as Vesilut; it appears only in transporter docking studies, and no published study supports its bladder label. Evidence: anecdotal. - [Vesugen](https://peptidelabs.app/peptides/vesugen/): Khavinson-series synthetic tripeptide KED (Lys-Glu-Asp), sold as a vascular bioregulator; studied in endothelial cell cultures and a mouse Alzheimer model, with uncontrolled Russian human reports. Evidence: preclinical. - [Vialox (Pentapeptide-3V)](https://peptidelabs.app/peptides/vialox-pentapeptide-3v/): Synthetic pentapeptide amide (Gly-Pro-Arg-Pro-Ala-NH2, pentapeptide-3) marketed as a nicotinic receptor antagonist for expression lines; published data are in silico and cell culture only. Evidence: preclinical. - [Vilon](https://peptidelabs.app/peptides/vilon/): Khavinson-series synthetic dipeptide KE (Lys-Glu); in rodents it slowed induced bladder tumours but did not extend mouse lifespan, and it reactivated chromatin in lymphocytes from older donors. Evidence: preclinical. - [VIP](https://peptidelabs.app/peptides/vip/): Vasoactive intestinal peptide, a 28-amino-acid neuropeptide acting at VPAC1 and VPAC2 receptors; studied for vasodilation, immune modulation and neuroprotection. Evidence: clinical. ## Categories - [Anti-Aging](https://peptidelabs.app/peptides/category/anti-aging/): 26 peptides - [Appetite](https://peptidelabs.app/peptides/category/appetite/): 13 peptides - [Bioregulator](https://peptidelabs.app/peptides/category/bioregulator/): 16 peptides - [Blend](https://peptidelabs.app/peptides/category/blend/): 9 peptides - [Cognitive](https://peptidelabs.app/peptides/category/cognitive/): 18 peptides - [Cosmetic](https://peptidelabs.app/peptides/category/cosmetic/): 20 peptides - [Fat Loss](https://peptidelabs.app/peptides/category/fat-loss/): 18 peptides - [Fertility](https://peptidelabs.app/peptides/category/fertility/): 5 peptides - [Growth Hormone](https://peptidelabs.app/peptides/category/growth-hormone/): 17 peptides - [Hair Growth](https://peptidelabs.app/peptides/category/hair-growth/): 6 peptides - [Healing & Recovery](https://peptidelabs.app/peptides/category/healing-recovery/): 20 peptides - [Hormonal](https://peptidelabs.app/peptides/category/hormonal/): 10 peptides - [Immune](https://peptidelabs.app/peptides/category/immune/): 12 peptides - [Metabolic](https://peptidelabs.app/peptides/category/metabolic/): 23 peptides - [Muscle Growth](https://peptidelabs.app/peptides/category/muscle-growth/): 18 peptides - [Neuroprotection](https://peptidelabs.app/peptides/category/neuroprotection/): 19 peptides - [Sexual Health](https://peptidelabs.app/peptides/category/sexual-health/): 4 peptides - [Skin Health](https://peptidelabs.app/peptides/category/skin-health/): 25 peptides - [Sleep](https://peptidelabs.app/peptides/category/sleep/): 4 peptides ## Guides - [Peptide Basics](https://peptidelabs.app/learn/basics/): What peptides are, how they work, and why people use them - [Getting Started Checklist](https://peptidelabs.app/learn/getting-started/): Everything you need before your first peptide experience - [Reconstitution Guide](https://peptidelabs.app/learn/reconstitution/): Step-by-step: how to properly mix your peptides - [Injection Techniques](https://peptidelabs.app/learn/injection-guide/): Safe subcutaneous and intramuscular injection methods - [Storage & Handling](https://peptidelabs.app/learn/storage/): How to store peptides to maintain potency and safety - [What to Expect](https://peptidelabs.app/learn/what-to-expect/): Timelines, side effects, and setting realistic expectations - [Common Mistakes](https://peptidelabs.app/learn/common-mistakes/): Pitfalls to avoid as a beginner — learn from others' errors - [Safety Guide](https://peptidelabs.app/learn/safety-guide/): Contraindications, drug interactions, and the warning signs that mean stop and get help. ## Developers - [Developer API and MCP server](https://peptidelabs.app/developers/): REST endpoints under https://api.peptidelabs.app/api/v1 and an MCP endpoint at https://api.peptidelabs.app/mcp, with install snippets and the attribution rule - [OpenAPI document](https://api.peptidelabs.app/api/v1/openapi.json): machine-readable description of API v1 ## Optional - [Full peptide reference](https://peptidelabs.app/llms-full.txt): every peptide page as markdown in one file (large) - [About PeptideLab](https://peptidelabs.app/about/): who maintains the site and how the data is reviewed - [Dosing calculator](https://peptidelabs.app/calculator): reconstitution and draw-volume math - [Verified vendors](https://peptidelabs.app/vendors): price comparison with third-party lab evidence - [Privacy](https://peptidelabs.app/privacy) - [Terms](https://peptidelabs.app/terms)